CDT Equity (CDT) Stock Price, News & Analysis

Company Overview

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Key Stats

• Today's Range: $0.61 to $0.67
• 50-Day Range: $0.60 to $1.89
• 52-Week Range: $0.61 to $2,198.40
• Volume: 55.29 million shs
• Average Volume: 12.00 million shs
• Market Capitalization: $1.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

CDT Equity Stock Analysis - MarketRank™

CDT Equity scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for CDT Equity.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CDT Equity is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CDT Equity is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.89% of the outstanding shares of CDT Equity have been sold short.

Short Interest Ratio / Days to Cover

CDT Equity has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CDT Equity has recently increased by 95.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CDT Equity does not currently pay a dividend.

Dividend Growth

CDT Equity does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.89% of the outstanding shares of CDT Equity have been sold short.

Short Interest Ratio / Days to Cover

CDT Equity has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CDT Equity has recently increased by 95.91%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.63

News Sentiment

CDT Equity has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for CDT Equity this week, compared to 1 article on an average week.

Search Interest

21 people have searched for CDT on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

MarketBeat Follows

1 people have added CDT Equity to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CDT Equity insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.72% of the stock of CDT Equity is held by insiders.

Percentage Held by Institutions

Only 3.29% of the stock of CDT Equity is held by institutions.

CDT Stock Analysis - Frequently Asked Questions

How have CDT shares performed this year?

CDT Equity's stock was trading at $102.90 on January 1st, 2025. Since then, CDT shares have decreased by 99.4% and is now trading at $0.6490.

How were CDT Equity's earnings last quarter?

CDT Equity Inc. (NASDAQ:CDT) posted its earnings results on Thursday, August, 14th. The company reported ($5.46) EPS for the quarter.

When did CDT Equity's stock split?

Shares of CDT Equity reverse split on the morning of Thursday, October 9th 2025.The 1-8 reverse split was announced on Thursday, October 9th 2025. The number of shares owned by shareholders will be adjusted after the market closes on Friday, October 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of CDT Equity?

Shares of CDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CDT Equity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CDT Equity investors own include BIOLASE (BIOL), Dare Bioscience (DARE), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Cara Therapeutics (CARA), Canoo (GOEV) and Jiuzi (JZXN).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/09/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CDT
• Previous Symbol: NASDAQ:CDT
• CIK: 1896212
• Web: www.conduitpharma.com
• Phone: 760-471-8536
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($435.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.80 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -350.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.45
• Quick Ratio: 1.45

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($73.54) per share
• Price / Book: -0.01

Miscellaneous

• Outstanding Shares: 3,060,000
• Free Float: 2,826,000
• Market Cap: $1.99 million
• Optionable: Not Optionable
• Beta: 1.81